Thermo Fisher Scientific Inc TMO said that its COVID-19 diagnostic tests can accurately detect the new coronavirus variant Omicron.
- The Omicron variant has more than 30 mutations in the spike protein alone.
- Last week, the World Health Organisation (WHO) classified the Omicron variant as a SARS-CoV-2 "variant of concern," saying it may spread more quickly than other forms.
- Thermo Fisher's TaqPath COVID-19 assays can report accurate results even if one of the gene targets is impacted by a mutation.
- Read Next: Thermo Fisher's COVID-19 Response Revenue Accounts For 22% In Q3 Sales, Boosts FY21 Outlook.
- Specific genotyping assays to detect the Omicron variant are being developed for Thermo Fisher's TaqMan Mutation Panel.
- The panel, which is currently used for research purposes, already has a menu of over 50 assays to assess confirmed COVID-19 cases for the presence of known variants and mutations.
- Also See: Qiagen Says Its COVID-19 PCR Tests Can Detect The New South African Variant.
- Price Action: TMO shares traded higher by 1.04% at $645.40 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in